Volume : 11, Issue : 05, May – 2024
Title:
COMPARISON OF BIOSIMILARS REGISTRATION WITH FEW COUNTRIES REGULATORY AUTHORITIES
Authors :
S. Manasa, MD. Rafiya Sowzine , B. Laxmi Prasanna, N. Suma,Dr. Shaik Shabeer, Dr. K. N. Venkateswara Rao
Abstract :
A drug master file (DMF) is a confidential, detailed document submitted by Active Pharmaceutical Ingredient (API) manufacturers to the U.S. Food and Drug Administration (FDA). A DMF contains the chemistry, manufacturing, and controls of a drug component. A drug master file is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its intellectual property from its partner while complying with regulatory requirements for disclosure of processing details. The DMF contains factual and complete information on a drug product’s chemistry, manufacture, stability, purity, impurity profile, packaging, and the cGMP status of any human drug product. The pharmaceutical industry is one of the most regulated industries; no drug would be marketed without the teams of medical researchers and other specialists who worked to make sure it receives regulatory authority’s approval. There is no legal or regulatory requirement to file a DMF. This study gives the information on regulatory requirements of Drug Master Files by Food and Drug Administration (USA), European Medicines Agency (Europe), Ministry of Health Labor and Welfare (Japan), Central Drug and Standard Control Organization (India) and WHO and their comparison.
Keywords: DMF, intellectual property, regulatory authority, FDA, WHO.
Cite This Article:
Please cite this article in press S.Manasa et al, Comparison Of Biosimilars Registration With Few Countries Regulatory Authorities.,Indo Am. J. P. Sci, 2024; 11 (5).
Number of Downloads : 10
References:
1. ASBM publishes paper on biosimilar naming. Posted 30/11/ 20. World HealthOrganization (WHO) Guidelineson Evaluation of Similar BiotherapeuticProducts (SBP), 2009
2. Availableat:http://www.gabionline.net/Biosimilars/General/ASBM-publishes- paper-on-biosimilar-naming.
3. Guidelines on Similar Biological Medicinal Products, London, UK, EuropeanMedicines Agency. 2005. CHMP/437/04.
4. Available at: http://Market Newsletter, 2011. Research & Markets: The Coming Age of Biosimilars – Regulatory Development and Alliance Strategies Intensify Interest in a Developing Market. Biomedical Market Newsletter, 6/19/2011, 703-704
5. Sagar J. Kanase et al; Biosimilar: An overview; 2013; vol.4, Issue 6; pgno- 2132-2134.
6. Rajaneesh Kumar Gaur et al ;Biosimilars The naming puzzle 2015;47(3).
7. Rajput Bane Singh et al; A Comparision of US,Europe,Japan,and Indiabiosimilar regulations2013; 5(2);35-39.
8. Krishna Undela et al; biosimilars an overview current situation inindia ;2012;01(07) 01